Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 4, Open-label, Single Arm Study to Optimize Implementation of CABENUVA for the Treatment of HIV-1, for Administration in U.S. Community-based Infusion Centers or Other Alternate Sites of Administration

NCT04982445 is registered in ClinicalTrials.gov with ViiV Healthcare as lead sponsor.

NCT NCT04982445
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04982445 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 4, Open-label, Single Arm Study to Optimize Implementation of CABENUVA for the Treatment of HIV-1, for Administration in U.S. Community-based Infusion Centers or Other Alternate Sites of Administration
Lead sponsor
ViiV Healthcare
Phase
Phase 4
Overall status
Completed
Start date
November 18, 2021
Completion date
January 31, 2024
Enrollment
44 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

hiv infections